Anne V Soerensen1, Frede Donskov2, Gregers G Hermann3, Niels V Jensen4, Astrid Petersen5, Henrik Spliid6, Rickard Sandin7, Kirsten Fode2, Poul F Geertsen8. 1. Department of Oncology, University Hospital of Copenhagen Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark. Electronic address: Anne.Vest.Soerensen@regionh.dk. 2. Department of Oncology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus, Denmark. 3. Department of Urology, University Hospital of Copenhagen Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. 4. Department of Oncology, Odense University Hospital, Sdr. Boulvard 29, 5000 Odense, Denmark. 5. Department of Pathology, Aalborg University Hospital, Ladegaardsgade 3, Postbox 561, 9100 Aalborg, Denmark. 6. Technical University of Denmark, Bygning 303B, 2800 Kongens Lyngby, Denmark. 7. Pfizer Oncology, Vetenskapsvägen 10, 19190 Sollentuna, Sweden. 8. Department of Oncology, University Hospital of Copenhagen Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark.
Abstract
AIM: To evaluate the implementation of targeted therapy on overall survival (OS) in a complete national cohort of patients with metastatic renal cell carcinoma (mRCC). METHODS: All Danish patients with mRCC referred for first line treatment with immunotherapy, TKIs or mTOR-inhibitors between 2006 and 2010 were included. Baseline and outcome data were collected retrospectively. Prognostics factors were identified using log-rank tests and Cox proportional hazard model. Differences in distributions were tested with the Chi-square test. RESULTS: 1049 patients were referred; 744 patients received first line treatment. From 2006 to 2010 we observed a significant increase in the number of referred patients; a significant increase in treated patients (64% versus 75%, P=0.0188); a significant increase in first line targeted therapy (22% versus 75%, P<0.0001); a significant increase in second line treatment (20% versus 40%, P=0.0104), a significant increased median OS (11.5 versus 17.2 months, P=0.0435) whereas survival for untreated patients remained unchanged. Multivariate analysis validated known prognostic factors. Moreover, treatment start years 2008 (HR 0.74, 95% CI, 0.55-0.99; P=0.0415), 2009 (HR 0.72, 95% CI, 0.54-0.96; P=0.0277) and 2010 (HR 0.63, 95% CI, 0.47-0.86; P=0.0035) compared to 2006, and more than two treatment lines received for patients with performance status 0-1 (HR 0.76, 95% CI, 0.58-0.99; P=0.0397) and performance status 2-3 (HR 0.19, 95% CI, 0.06-0.60; P=0.0051) were significantly associated with longer OS. CONCLUSION: This retrospective study documents that the implementation of targeted therapy has resulted in significantly improved treatment rates and overall survival in a complete national cohort of treated mRCC patients.
AIM: To evaluate the implementation of targeted therapy on overall survival (OS) in a complete national cohort of patients with metastatic renal cell carcinoma (mRCC). METHODS: All Danish patients with mRCC referred for first line treatment with immunotherapy, TKIs or mTOR-inhibitors between 2006 and 2010 were included. Baseline and outcome data were collected retrospectively. Prognostics factors were identified using log-rank tests and Cox proportional hazard model. Differences in distributions were tested with the Chi-square test. RESULTS: 1049 patients were referred; 744 patients received first line treatment. From 2006 to 2010 we observed a significant increase in the number of referred patients; a significant increase in treated patients (64% versus 75%, P=0.0188); a significant increase in first line targeted therapy (22% versus 75%, P<0.0001); a significant increase in second line treatment (20% versus 40%, P=0.0104), a significant increased median OS (11.5 versus 17.2 months, P=0.0435) whereas survival for untreated patients remained unchanged. Multivariate analysis validated known prognostic factors. Moreover, treatment start years 2008 (HR 0.74, 95% CI, 0.55-0.99; P=0.0415), 2009 (HR 0.72, 95% CI, 0.54-0.96; P=0.0277) and 2010 (HR 0.63, 95% CI, 0.47-0.86; P=0.0035) compared to 2006, and more than two treatment lines received for patients with performance status 0-1 (HR 0.76, 95% CI, 0.58-0.99; P=0.0397) and performance status 2-3 (HR 0.19, 95% CI, 0.06-0.60; P=0.0051) were significantly associated with longer OS. CONCLUSION: This retrospective study documents that the implementation of targeted therapy has resulted in significantly improved treatment rates and overall survival in a complete national cohort of treated mRCC patients.
Authors: Lauren C Harshman; Nils Kroeger; Sun Young Rha; Frede Donskov; Lori Wood; Srinivas K Tantravahi; Ulka Vaishampayan; Brian I Rini; Jennifer Knox; Scott North; Scott Ernst; Takeshi Yuasa; Sandy Srinivas; Sumanta Pal; Daniel Y Heng; Toni K Choueiri Journal: Clin Genitourin Cancer Date: 2014-03-15 Impact factor: 2.872
Authors: Christian Beisland; Tom B Johannesen; Olbjorn Klepp; Ulrika Axcrona; Knut Martin Torgersen; Jan Kowalski; Oddvar Solli; Rickard Sandin; Jan Oldenburg Journal: Onco Targets Ther Date: 2017-01-16 Impact factor: 4.147
Authors: Ning Yi Yap; Retnagowri Rajandram; Keng Lim Ng; Jayalakshmi Pailoor; Ahmad Fadzli; Glenda Carolyn Gobe Journal: Biomed Res Int Date: 2015-09-13 Impact factor: 3.411